American Bitcoin Corp

ABTC Q2 2026

Reported: 2026-08-05

The stock gained 11.2% following earnings, driven by higher-than-expected Bitcoin production and revenue growth despite falling Bitcoin prices, highlighting operational execution as the key positive catalyst.

Key takeaways

Bitcoin production rose approximately 14% quarter-over-quarter to 932 BTC, marking a record high driven by full-scale contribution from the Drumheller site’s new capacity.
Revenue increased 8% sequentially to roughly $67 million despite a 12% decline in the Bitcoin price, with growth primarily attributable to higher production and a downward adjustment in network difficulty.
Gross margin compressed modestly to 49% from 52% due to the price decline, but underlying costs remained stable with only a slight rise in energy expenses.
Cost to mine stayed largely flat, increasing less than 1% to about $36,500 per Bitcoin, emphasizing operational discipline amid volatility.
The strategic reserve grew 14% to 8,002 Bitcoin, fueled by mine production plus selective market purchases, with no Bitcoin sales from the balance sheet during the quarter.

View recap

Adeia Inc. Common Stock

ADEA Q2 2026

Reported: 2026-08-05

Adeia's stock jumped 17.1% following an earnings report that highlighted strong execution on high-value license agreements, solid cash generation, and an upgrade to long-term revenue targets, signaling investor confidence in the company’s growth trajectory despite ongoing Pay-TV headwinds.

Key takeaways

Reported Q2 revenue of $96.1 million and adjusted EBITDA margin of 58.7%.
Generated $54.6 million in cash from operations, ending the quarter with $137 million in cash.
Closed 6 new license agreements including major deals with Microsoft, AMD, Google, RPX, and L’Oreal.
Non-Pay-TV recurring revenue surged 54% year-over-year and is now nearly twice the size of Pay-TV revenue.
Raised long-term revenue target from $500 million to $600 million, driven by optimism in semiconductor markets and expanding media and e-commerce portfolios.

View recap

Advanced Energy Industries, Inc.

AEIS Q2 2026

Reported: 2026-08-05

The stock surged 17.9% following Advanced Energy’s Q2 report, driven by stronger-than-expected revenue growth across semiconductor and data center segments as well as improved margin execution.

Key takeaways

Semiconductor revenue grew sequentially by over 27%, driven by robust demand for leading-edge memory, logic, and intensified etch and dep processes.
Data Center Computing segment now anticipated to grow at least 50% for the full year, supported by increased hyperscaler demand and expanding second wave customer opportunities.
Gross margin improvement attributed to manufacturing efficiencies, a richer product mix, and targeted pricing actions to offset input cost inflation.
New product introductions are accelerating, with several design wins beginning to ramp in plasma power, system power, industrial, and medical segments.
Capacity investments continue, including expansion in Malaysia and potential first production from new Thailand factory in Q4, positioning for approximately $5 billion of revenue-generating capacity.

View recap

Allegiant Travel Company

ALGT Q2 2026

Reported: 2026-08-05

Allegiant's Q2 results drove a 7.1% stock gain as unit revenue growth notably outpaced unit cost increases, supported by strong commercial initiatives and early success integrating Sun Country.

Key takeaways

Combined Allegiant and Sun Country delivered over 20% year-over-year improvement in TRASM for both airlines.
Unit revenue growth exceeded unit cost inflation, contributing to leading operating margins for the third consecutive quarter.
Strong operational execution highlighted by industry-leading controllable completion and mishandled bag metrics; in-flight NPS remains healthy.
Progress on Sun Country integration includes combined flight search and booking functionality and initial procurement consolidation.
Commercial innovation advances with 24% annual increase in co-brand credit card remuneration and a new Expedia OTA partnership expanding customer reach.

View recap

Alpha Services and Holdings S.A.

ALPHA.AT Q2 2026

Reported: 2026-08-05

Alpha Bank shares rose modestly by 2.6% following results that showed steady profit growth and strong strategic execution, though the market remained cautious given the absence of a more significant upside surprise.

Key takeaways

Reported close to EUR 0.5 billion in profits for H1 2026, up 6.5% on a normalized basis versus last year.
Net interest income increased by 7.3%, driven by loan book growth.
Fees rose 34% on headline basis (24% excluding Prodea dividends), benefiting from investment and M&A initiatives.
Cost-to-income ratio stable at 39%, reflecting operational leverage within guidance.
Cost of risk remained benign at 42 basis points, with performing loans growing double digits and 87% of the annual net credit expansion target hit in H1.

View recap

Amadeus IT Group, S.A.

AMS.MC Q2 2026

Reported: 2026-08-05

The stock edged up modestly by 0.6% following a report of generally stable results amid a cautious outlook driven by geopolitical headwinds that pressured traffic and prompted a wider-than-normal 2026 guidance range, particularly for the Air Distribution segment.

Key takeaways

Revenue and adjusted EBIT each grew by 5% at constant currency in H1 2026, with adjusted diluted EPS up 7%.
The Middle East geopolitical situation dampened global traffic, leading IATA to report negative growth in April and May—the first such decline in 15 years excluding the pandemic.
Management revised full-year outlook downward, especially at the lower end, citing reduced air traffic and related impacts on Air Distribution.
Commercial momentum remained healthy with new customer wins across airline IT, airport IT, hospitality, and payments solutions, supporting diversified revenue streams.
Significant AI advances included progressing Nevio airline IT adoption with major carriers, launching an Amadeus advertising platform with Accenture, and expanding strategic partnerships with Microsoft and Google.

View recap

Backblaze Inc. Class A Common Stock

BLZE Q2 2026

Reported: 2026-08-05

Backblaze’s Q2 results materially outperformed expectations, driving a 44.2% stock gain as revenue, margins, and AI-related customer growth all accelerated, highlighted by a landmark $335 million multi-year contract with CoreWeave.

Key takeaways

Revenue reached $42.7 million, beating the high end of guidance by $2.5 million.
Adjusted EBITDA margin came in at 30%, 700 basis points above the high end of guidance, reflecting improved operational leverage.
B2 segment growth accelerated to 34% year-over-year, demonstrating strong underlying momentum.
The $335 million multi-year contract with CoreWeave—the largest in company history—validates Backblaze's positioning as critical infrastructure for AI storage needs.
Customer base expansion notable with 235 customers now contributing over $50,000 ARR each, up 57% year-over-year; this cohort grew ARR by 67%, underscoring increasing reliance on Backblaze by enterprise clients.

View recap

Cohen & Company Inc.

COHN Q2 2026

Reported: 2026-08-05

Shares declined 5.5% following earnings as investors reacted negatively to margin compression and increased losses from equity affiliates, particularly related to the Columbus Circle Capital II SPAC. Despite revenue gains, cautious outlook elements and escalating compensation expenses appear to have weighed on sentiment.

Key takeaways

Net income rose to $3.6 million ($0.94 per diluted share), up from $1.5 million last quarter and $1.4 million year-over-year.
Investment banking and new issue revenue increased to $54 million, driven by SPAC-related M&A and IPO activity within CCM.
Compensation and benefits expense rose $6.9 million sequentially to $48.2 million, reflecting higher variable incentives tied to revenue fluctuations.
Losses from equity method affiliates widened sharply to $3 million, primarily due to the Columbus Circle Capital II SPAC, partially offset by noncontrolling interest credits.
Asset management revenue declined both sequentially and year-over-year, suggesting softness outside core investment banking operations.

View recap

Crescent Energy Company

CRGY Q2 2026

Reported: 2026-08-05

Shares declined 1.7% after earnings, reflecting investor caution despite operational improvements and raised production guidance; concerns linger over the sustainability of margin gains and the realization of synergy targets amid a cautious outlook.

Key takeaways

Total production reached approximately 335,000 barrels of oil equivalent per day, about 2% above the midpoint of original full-year guidance.
Oil production was roughly 4% above midpoint, contributing to raised full-year production targets.
Adjusted operating expenses came in nearly 10% better than midpoint forecast, reflecting cost discipline across assets.
Annualized synergy capture from the Permian acquisition increased to $190 million, with the target range raised to $250–300 million, roughly triple the original estimate.
Despite operational progress and record free cash flow of $418 million, the stock’s modest decline suggests investor skepticism about future margin sustainability and growth outlook.

View recap

AXA SA

CS.PA Q2 2026

Reported: 2026-08-05

AXA shares edged down 0.6% post-earnings as the market appeared cautious despite stable margins and positive growth; modest pressures from Middle East losses and cautious forward commentary likely weighed on sentiment.

Key takeaways

Reported 5% organic top-line growth and 8% underlying EPS growth, nearing the upper end of the company’s 6-8% target range.
P&C combined ratio stable at 90.1%, though up 30 bps excluding the Prima portfolio due to EUR 0.1 billion losses from AXA XL in the Middle East.
AXA XL technical margin excluding Middle East impact was stable, with pricing holding up better than the market amid cycle challenges.
Investment income increased, driven by higher reinvestment yields and asset reallocation to private debt, offsetting unwind increases.
Life & Health premiums grew 8% with 11% earnings growth, supported by strong performance in both short-term and long-term businesses.

View recap

Echo Global Logistics, Inc.

ECHO Q2 2026

Reported: 2026-08-05

EchoStar’s shares responded positively with an 8.9% gain, reflecting investor approval of the company’s cautious approach to capital allocation and clear demarcation of risk amid Hughes Corporation’s Chapter 11 filing. The market appears to favor EchoStar’s disciplined capital strategy and ongoing operations despite the bankruptcy of a subsidiary.

Key takeaways

Hughes Corporation filed for Chapter 11 bankruptcy following a $1.5 billion bond maturity default; the restructuring is limited to Hughes entities and does not impact EchoStar Corporation or its international assets.
Hughes operations are expected to continue uninterrupted during bankruptcy, honoring employee payroll and customer commitments.
The Board has increased share repurchase authorization to up to $5 billion, signaling potential capital return if investment opportunities do not meet return hurdles.
Management emphasized prioritizing investments in existing businesses and opportunities through EchoStar Capital before share buybacks or dividends.
Boost Mobile continues to struggle with subscriber losses despite being slightly cash flow positive in the quarter; new leadership aims to implement strategic initiatives to improve performance.

View recap

Diamondback Energy, Inc.

FANG Q2 2026

Reported: 2026-08-05

Diamondback’s shares declined 5.5% as investors reacted negatively to increased uncertainty around production growth and cautious commentary on natural gas volumes, signaling concerns over deceleration and a conservative near-term outlook despite operational efficiencies.

Key takeaways

Production growth was modest, with management highlighting a 4% increase year-to-date and signaling potential low single-digit organic growth into 2027 rather than more aggressive expansion.
Management emphasized inventory draws supporting oil prices but acknowledged significant uncertainty around demand and prices, tempering visibility on growth potential.
Well productivity remains a bright spot, with continued operational improvements and low cost per well driving higher net present value per acre.
Natural gas egress issues showed some relief with improved pricing at Waha and new pipeline progress, but gas remains a non-core, somewhat uncertain element in the near term.
The tone around capital allocation and production guidance implied caution, likely contributing to investor disappointment with the outlook.

View recap

X Financial

FFH.TO Q2 2026

Reported: 2026-08-05

Fairfax’s shares declined modestly by 0.6% following Q2 results as gains in underwriting and investment income were partly offset by weaker profits from associates and mark-to-market losses on bonds amid rising interest rates, dampening the overall outlook.

Key takeaways

Operating income from insurance and reinsurance was $1.1 billion, with underwriting income increasing to $459 million from $427 million year-over-year.
Interest and dividend income rose 11% to $737 million, reflecting a larger portfolio and higher government yields.
Profits of associates decreased substantially to $43 million from $131 million, impacted by mark-to-market losses on Helios Fairfax Partners and the Waterous fund.
Net investment gains totaled $769 million, boosted by the $838 million pretax profit on a partial sale of Poseidon, but offset by unrealized losses on Orla and bonds due to higher interest rates.
Gross premiums grew 4.1% to $9.4 billion, with mixed performance across insurance segments; some premium softness noted in competitive lines and reinsurance.

View recap

Grab Holdings Limited Class A Ordinary Shares

GRAB Q2 2026

Reported: 2026-08-05

Grab’s shares rose 6.3% following an earnings report that highlighted strong on-demand growth and raised full-year guidance, driven by consolidation of Superbank and the acquisition of Stash, signaling investor approval of the company’s expanding financial services and improving margins.

Key takeaways

On-demand Gross Merchandise Value (GMV) increased 21% year-over-year to $6.5 billion, with monthly transacting users reaching a record 54 million.
Adjusted EBITDA grew 54% year-over-year to $168 million, expanding margins to 16.9% from 13.3%, marking 18 consecutive quarters of EBITDA growth.
Full year 2026 guidance was raised, reflecting continued strong demand in core businesses and the addition of Superbank and Stash consolidated results.
Deliveries accelerated to 24% year-over-year growth (constant currency), fintech segment nearing adjusted EBITDA profitability in H2 2026, and mobility segment grew 18% despite persistent elevated fuel prices.
AI integration scaled significantly, cutting AI interaction costs by half and driving operational efficiencies, supporting margin expansion and product innovation.

View recap

HealthStream, Inc.

HSTM Q2 2026

Reported: 2026-08-05

Shares rose 6.3% following Q2 results as revenue growth of 12.5% and adjusted EBITDA growth of 16.9% both came in ahead of expectations, supported by strong traction in the career networks segment and increased full-year guidance.

Key takeaways

Revenue reached a record $83.7 million, up 12.5% year-over-year.
Adjusted EBITDA increased 16.9% to $20.6 million, with operating income up 41.4% year-over-year.
Management raised full-year revenue and adjusted EBITDA guidance based on strong first-half results.
Career networks, particularly myClinicalExchange, expanded 29% YoY, driven by investments including 15 new positions added beyond initial budgets.
Company highlighted a strong balance sheet with $66.7 million cash, no long-term debt, and available line of credit, supporting M&A and strategic investments.

View recap

Ichor Holdings, Ltd.

ICHR Q2 2026

Reported: 2026-08-05

Shares fell 5.3% after the quarter as investors reacted negatively to persistent part shortages delaying revenue recognition and the cautious tone around supply chain constraints, which cast doubt on near-term growth despite positive margin trends.

Key takeaways

Reported revenue of $295 million, up 15% sequentially, but some expected revenue was pushed into the following week due to isolated part shortages.
Gross margin improved by 130 basis points to 14.1%, exceeding guidance, driven by product mix and footprint realignment.
EPS more than doubled from Q1, reaching $0.34, the highest quarterly earnings in three years.
Management highlighted resolved supply issues but still emphasized ongoing investments to mitigate supply chain pain points, keeping some caution in outlook.
Company capacity stands at $500 million quarterly revenue currently, with plans to expand to over $3 billion annually through targeted investments in proprietary components.

View recap

IMI plc

IMI.L Q2 2026

Reported: 2026-08-05

IMI's shares inched up 0.5% post-results, reflecting a largely stable reaction to solid but unsurprising organic growth and margin improvement, alongside a confirmed full-year outlook.

Key takeaways

Organic revenue rose 5% in H1 2026, with growth seen across all sectors, including a 22% increase in Growth Hub orders.
Organic adjusted operating profit increased 8%, lifting adjusted operating margin by 50 basis points to 18.7%.
Adjusted basic EPS grew 13% to 63.4p, supported by disciplined capital allocation and operating leverage.
Free cash flow improved sharply to GBP 171 million from GBP 30 million a year ago, driven by strong cash conversion and working capital management.
Full-year guidance was reaffirmed, with mid-single-digit organic revenue growth and adjusted EPS expected between 136p and 142p.

View recap

Jazz Pharmaceuticals plc

JAZZ Q2 2026

Reported: 2026-08-05

Jazz Pharmaceuticals shares rose 3.5% following a quarter driven by broad-based portfolio growth with multiple product lines exceeding expectations, particularly Xywav and Epidiolex. The market rewarded strong commercial execution and confidence in upcoming oncology launches.

Key takeaways

Total revenue reached $1.2 billion, up 16% year-over-year, reflecting sustained demand and effective commercialization across key products.
Xywav net product sales grew 13% to $471 million, supported by continued new patient additions (+525 in the quarter) and an expanding active patient base now exceeding 17,000.
Epidiolex sales increased 16% to $292 million, benefiting from ongoing educational efforts and the introduction of a novel capsule formulation targeting improved adherence in adult patients.
Oncology portfolio showing early momentum as Ziihera generated $15 million in second-line BTC sales, capturing over 50% U.S. market share in the segment.
Management highlighted readiness to launch zanidatamab in first-line HER2-positive metastatic GEA, leveraging existing commercial infrastructure to drive near-term growth.

View recap

Krystal Biotech, Inc.

KRYS Q2 2026

Reported: 2026-08-05

Krystal Biotech’s shares fell 4.8% following the quarter, driven primarily by a disappointing outlook on pricing and reimbursement progress in Europe leading to a revenue reserve in Germany. Despite operational momentum, investor concerns over continued market access hurdles and muted near-term revenue growth weighed on sentiment.

Key takeaways

Europe and Japan revenues remained broadly flat in Q2, impacted by a reserve provision related to uncertain pricing outcomes in Germany.
Ongoing reimbursement negotiations in key EU markets like Germany, Italy, and Spain are delaying sustained revenue growth, with formal pricing decisions expected to continue through 2026 and 2027.
U.S. net revenue was $91.6 million, reflecting steady commercial traction and expansion into community settings.
International launches show growth in patient and treatment volumes but face operational challenges, including fragmented care centers in Germany and access restrictions in France and Japan.
Multiple upcoming regulatory submissions in other countries are planned, but market access remains a significant near-term obstacle to revenue scaling.

View recap

NatWest Group plc

NWG.L Q2 2026

Reported: 2026-08-05

NatWest’s shares rose 3.2% following results that showed better-than-expected income growth, driven by broad-based customer asset and liability expansion and strengthened margins, which underpinned an upgraded 2026 returns guidance.

Key takeaways

Income, excluding notable items, rose 5.4% in Q2 to £4.4 billion, supported by 15% growth in noninterest income (£124 million).
Customer assets and liabilities grew 13.4% year-on-year, led by £9.7 billion broad-based loan growth and £2.8 billion deposit increase; assets under management rose notably due to the Evelyn Partners acquisition.
Return on tangible equity improved to 21% in Q2, with full year guidance upgraded to above 19%.
Operating leverage improved as income growth (8.9%) outpaced cost increase (4.5%), pushing the cost-to-income ratio down 2.8 percentage points to 46%.
Credit quality remained strong with an impairment charge of £140 million (13bps), and unchanged guidance for a loan impairment rate below 25 basis points in 2026.

View recap

Palantir Technologies Inc.

PLTR Q2 2026

Reported: 2026-08-05

Shares surged 32.2% as Palantir delivered exceptional revenue growth driven by accelerating U.S. commercial and government business, highlighted by record deal sizes and impressive free cash flow generation.

Key takeaways

Revenue grew 93% year-over-year, led by a 115% increase in the U.S. business, which now accounts for over 81% of total revenue.
U.S. commercial revenue accelerated by 149% year-over-year and 28% sequentially.
U.S. government revenue rose 90% year-over-year and 18% sequentially, sustaining strong momentum across defense and civil segments.
Closed 220 deals worth $1 million or more, including 98 deals over $5 million and 73 deals exceeding $10 million, all record highs.
Generated $1.22 billion in adjusted free cash flow and achieved a Rule of 40 score of 155%, underscoring operational efficiency amid rapid growth.

View recap

PostNL N.V.

PNL.AS Q2 2026

Reported: 2026-08-05

PostNL shares jumped 6.9% following the half-year results, driven by stronger-than-expected cost savings and operational efficiency gains that offset volume pressures and a cautious market environment.

Key takeaways

Revenue remained stable at EUR 1.6 billion, roughly flat year-over-year amid challenging market conditions.
Normalized EBIT edged up slightly, supported by disciplined volume management and an improved average price per parcel (+5%).
Execution of the volume-to-value strategy gained traction despite lower volumes, especially from Asian e-commerce due to new import duties.
Additional cost savings initiative launched targeting EUR 75 million for 2027–28, building on EUR 40–50 million savings expected for 2026 (EUR 24 million achieved halfway).
Strong operational improvements, including AI-driven logistics optimizations and better network utilization, underpin margin resilience despite intensified competition.

View recap

FreightCar America, Inc.

RAIL Q2 2026

Reported: 2026-08-05

The stock gained 7.2% as FreightCar America reported exceptional new order intake and substantial backlog growth, signaling strong commercial momentum that outweighed concerns about delayed production and revised 2026 delivery guidance.

Key takeaways

New orders totaled approximately 3,000 units, including 2,600 new railcars, representing about 45% of total industry new railcar orders for the quarter.
Backlog surged 93% sequentially in units to 3,972 and 121% in value to roughly $344 million, providing visibility into deliveries through 2028.
The company deferred some production initially planned for 2026 into early 2027, leading to a lowered full-year revenue and delivery outlook.
Aftermarket revenues grew 13% year-over-year, bolstered by organic growth and a recent acquisition, contributing to a more stable, higher-margin revenue stream.
Operational improvements delivered a 50% productivity gain over two years; a significant structural realignment at the Castaños facility was completed to lock in cost benefits moving forward.

View recap

Sabra Health Care REIT, Inc.

SBRA Q2 2026

Reported: 2026-08-05

Shares declined 2.4% following Sabra Healthcare REIT’s Q2 report, reflecting investor caution despite stable fundamentals, as the market appeared unimpressed by modest growth and mixed margin performance amid a cautious tone on portfolio transitions.

Key takeaways

Normalized FFO per share was flat sequentially at $0.38 and up 3% year-over-year; normalized AFFO per share increased 5% year-over-year to $0.40.
Total cash NOI rose sequentially by $5.6 million to $144.3 million, driven by managed senior housing and triple-net portfolio improvements.
Managed senior housing portfolio showed strong sequential revenue (+9.6%) and cash NOI growth (+14.4%) with 130 basis points of margin expansion; occupancy improved 170 basis points to 88.2%.
Triple-net skilled nursing portfolio showed improved rent coverage, but triple-net senior housing experienced a drop in occupancy and coverage due to asset transition to the SHOP segment.
Leverage improved to 4.61%, and Medicaid and Medicare rate adjustments were in line with expectations, but cautious comments on asset transition and mixed operational signals likely weighed on sentiment.

View recap

Compagnie de Saint-Gobain S.A.

SGO.PA Q2 2026

Reported: 2026-08-05

Shares jumped 9.8% on solid sequential acceleration in organic growth and margin resilience, fueled by broad-based regional strength and continued capital deployment into high-growth markets.

Key takeaways

Group organic sales grew 0.7% in H1 2026 but accelerated to +3.5% in Q2, with all regions contributing, led by Asia Pacific (+7%) and Europe (+4%).
EBITDA margin held steady at a strong 15.4%, supported by pricing gains and operational discipline despite foreign exchange headwinds and inflationary pressures.
Recurring net income was €1.7 billion, with EPS down 2.6% in local currencies mainly due to FX impacts and ongoing investments.
Free cash flow was robust at €2.1 billion, reflecting a 65% conversion of EBITDA, and the company maintained a solid balance sheet with net debt at 1.6x EBITDA.
Strategic capital allocation remains a focus, with €3 billion of divestments and acquisitions closed year-to-date and 90% of investments directed toward higher-growth markets.

View recap

Snap Inc.

SNAP Q2 2026

Reported: 2026-08-05

Snap’s shares surged 23.5% following an encouraging quarter marked by strong user growth and accelerating revenue, driven notably by rapid expansion in Snap’s other revenue streams and improving advertising momentum.

Key takeaways

Monthly active users grew to 971 million, and daily active users reached 493 million, underscoring ongoing scale expansion.
Total revenue increased 19% year-over-year to $1.6 billion; advertising revenue rose 9% to $1.28 billion while other revenue soared 85% to $316 million.
Gross margin improved to 58%, supported by AI-driven efficiencies in ad delivery and internal operations.
Operating cash flow was positive at $176 million, with free cash flow of $121 million, now the company’s primary financial metric.
AI enhancements drove notable gains in advertiser outcomes: cost per install down 8%, cost per purchase down 18%, and app purchase volume up 128%, benefiting advertiser retention and spend.

View recap

Tidewater Inc.

TDW Q2 2026

Reported: 2026-08-05

Shares rallied 12.2% following a better-than-expected quarter driven by stronger-than-anticipated day rates and utilization, particularly in Europe and the Middle East, alongside expanded gross margins that exceeded prior guidance.

Key takeaways

Revenue totaled $342.3 million, with gross margin just under 47%, nearly 3 percentage points above prior expectations; excluding $6.8 million of conflict-related expenses, margin would have been approximately 49%.
Weighted average leading edge day rates rose about 7.5% sequentially, reflecting tight supply-demand dynamics.
Utilization benefited from improved operational uptime and deferred dry docks on seven vessels, pushed from Q2 to later in the year.
Free cash flow nearly doubled quarter-over-quarter to $64 million, supported by operational execution and dry dock timing.
Wilsons' acquisition expected to close around September 1st, with net leverage forecasted to increase to ~0.8x by Q3-end; balance sheet and liquidity remain robust with $850 million on hand.

View recap

TG Therapeutics, Inc.

TGTX Q2 2026

Reported: 2026-08-05

Shares dropped 6.3% following the quarter as investors reacted negatively to a cautious outlook and the implied challenges expanding beyond the core BRIUMVI IV franchise, despite steady commercial execution and pipeline progress.

Key takeaways

BRIUMVI sales continued to grow, approaching a $1 billion annualized run rate with expanding physician adoption and new patient starts.
Positive Phase III ENHANCE data supported a simplified single-infusion initiation, potentially easing patient and provider burden by mid-2027.
Subcutaneous BRIUMVI showed promising Phase I bioavailability data; Phase III results are expected late this year or early next, with the subcutaneous formulation poised to roughly double the addressable market.
Early-stage expansion efforts include Phase I in myasthenia gravis and Phase II initiation in treatment-resistant schizophrenia, though these remain speculative and modest investments.
The cautious tone around broader franchise growth, timing uncertainties around subcutaneous data, and exploratory pipeline projects likely tempered enthusiasm, contributing to the stock’s material decline.

View recap

Tyson Foods, Inc.

TSN Q3 2026

Reported: 2026-08-05

Tyson Foods' shares rose modestly by 1.3% following Q3 results that show steady but uneven execution, with margin pressure in Prepared Foods partially offset by continued strength in Chicken. The market response suggests cautious optimism on a mixed quarter without clear upside surprises.

Key takeaways

Prepared Foods sales increased 1.7% YoY to $2.6 billion, but segment operating income declined slightly due to $30 million of higher commodity costs that outpaced pricing efforts, compressing margins to 12.6%.
Chicken segment operating income rose by $40 million YoY to $488 million, with a strong margin of 11.2%, supported by 3.8% retail and foodservice volume growth, nearly four times overall volume growth.
Prepared Foods achieved its highest volume, unit, and dollar share in Q3, driven by disciplined promotional execution and targeted marketing, notably strong gains in Hillshire Snacking (+18.4%) and Hillshire Farm Lunch Meat (+7%).
Commodity cost pressures remain a headwind for Prepared Foods, with anticipated margin benefits expected only later in Q4 and into fiscal 2027.
The company's innovation strategy continues, emphasizing protein-centric, convenient offerings with recent launches like Jimmy Dean high-protein and Hillshire Reserve lunchmeat aimed at capturing premium and younger consumer segments.

View recap

Vertex, Inc.

VERX Q2 2026

Reported: 2026-08-05

Vertex shares declined 4.0% post-earnings as investors reacted to slower-than-expected cloud conversions and tepid expansion within the installed base, signaling concerns over growth execution despite stable retention and margin expansion.

Key takeaways

Revenue grew 10.5% year-over-year to $204 million, hitting the high end of guidance but driven by mixed customer expansion results.
Adjusted EBITDA rose 33% to $51 million, with margin expansion of 4+ percentage points to 25%, reflecting improved cost discipline.
Gross revenue retention held steady at 95% and net revenue retention at 105%, indicating a durable customer base.
Expansion within existing customers and new logo wins underperformed expectations, partly due to sluggish cloud migration activity.
E-invoicing demonstrated strong momentum, notably driven by mandates in France and upcoming German requirements, with several six-figure enterprise deals closed.

View recap

Vertex Pharmaceuticals Incorporated

VRTX Q2 2026

Reported: 2026-08-05

Vertex's shares were largely unchanged following Q2 results, reflecting a mixed signal as the company demonstrated steady revenue growth and pipeline progress but provided no clear catalyst to significantly move the stock.

Key takeaways

Total revenue increased 12% year-over-year, driven primarily by the cystic fibrosis portfolio and contributions from newer products CASGEVY and JOURNAVX.
The FDA accepted the BLA for Pove in IgAN with a November 30 PDUFA date, following strong Phase III interim results.
Regulatory progress included expanded labeling for CASGEVY in younger patients and global submissions for ALYFTREK and TRIKAFTA in younger CF populations.
Pipeline advances continued with late-stage enrollment milestones reached in ADPKD and AMKD programs and ongoing early-stage studies for next-generation CFTR modulators.
The announced acquisition of Crinetics Pharmaceuticals aims to broaden Vertex’s rare disease footprint, adding potential for future growth, though no near-term financial impact was detailed.

View recap

The Williams Companies, Inc.

WMB Q2 2026

Reported: 2026-08-05

Williams reported a largely in-line quarter with flat stock price reaction following modest EBITDA growth and incremental guidance raises. While underlying business growth and strategic transactions support the outlook, the market appears unmoved amid ongoing execution risks and cautious commentary on scaling Power Innovation projects.

Key takeaways

Q2 EBITDA increased 6% year-over-year, and 10% year-to-date, reaching $1.92 billion, driven by Transmission and Gulf businesses.
Gulf segment revenue rose 23%, fueled by recent expansion projects, with Northeast Gathering & Processing also up 8%.
Announced a $5.34 billion Power Innovation joint venture with Blackstone, creating balance sheet capacity and improving project returns by approximately 56% on invested capital over primary contract terms.
Completed strategic acquisition of Momentum Midstream, complementing Williams’ footprint in the Haynesville and Gulf Coast regions.
Raised full-year 2026 EBITDA guidance midpoint by $200 million and increased long-term EBITDA growth target to 11+% CAGR through 2030.

View recap

Earnings Recaps

American Bitcoin Corp

Adeia Inc. Common Stock

Advanced Energy Industries, Inc.

Allegiant Travel Company

Alpha Services and Holdings S.A.

Amadeus IT Group, S.A.

Backblaze Inc. Class A Common Stock

Cohen & Company Inc.

Crescent Energy Company

AXA SA

Echo Global Logistics, Inc.

Diamondback Energy, Inc.

X Financial

Grab Holdings Limited Class A Ordinary Shares

HealthStream, Inc.

Ichor Holdings, Ltd.

IMI plc

Jazz Pharmaceuticals plc

Krystal Biotech, Inc.

NatWest Group plc

Palantir Technologies Inc.

PostNL N.V.

FreightCar America, Inc.

Sabra Health Care REIT, Inc.

Compagnie de Saint-Gobain S.A.

Snap Inc.

Tidewater Inc.

TG Therapeutics, Inc.

Tyson Foods, Inc.

Vertex, Inc.

Vertex Pharmaceuticals Incorporated

The Williams Companies, Inc.

Community

Earnings Recaps

American Bitcoin Corp

Adeia Inc. Common Stock

Advanced Energy Industries, Inc.

Allegiant Travel Company

Alpha Services and Holdings S.A.

Amadeus IT Group, S.A.

Backblaze Inc. Class A Common Stock

Cohen & Company Inc.

Crescent Energy Company

AXA SA

Echo Global Logistics, Inc.

Diamondback Energy, Inc.

X Financial

Grab Holdings Limited Class A Ordinary Shares

HealthStream, Inc.

Ichor Holdings, Ltd.

IMI plc

Jazz Pharmaceuticals plc

Krystal Biotech, Inc.

NatWest Group plc

Palantir Technologies Inc.

PostNL N.V.

FreightCar America, Inc.

Sabra Health Care REIT, Inc.

Compagnie de Saint-Gobain S.A.

Snap Inc.

Tidewater Inc.

TG Therapeutics, Inc.

Tyson Foods, Inc.

Vertex, Inc.

Vertex Pharmaceuticals Incorporated

The Williams Companies, Inc.

Community

Trending This Week

Notifications